ZENTderma
- Address
- lock Available on a paid plan
Dermatology Research at ZENTderma
Clinical research at ZENTderma focuses on Skin and Connective Tissue Diseases, with studies centered on common but clinically important dermatologic conditions. The trials are designed to assess how well new or existing treatments work and how safe they are for patients.
- Actinic Keratosis of the scalp and face
- Skin candidiasis with moderate to severe inflammation
- Evaluation of treatment effectiveness and safety in dermatology
These studies aim to improve care for patients with sun-related precancerous skin changes and yeast-related skin infections, helping clarify which therapies offer the best clinical benefit.
Actinic Keratosis Studies
One major area of research at this site is Actinic Keratosis, a skin condition often linked to long-term sun exposure. The trial activity is focused on testing whether a topical treatment can achieve better clearance of affected skin than a comparison approach.
- Actinic Keratosis of the scalp
- Actinic Keratosis of the face
- Testing a therapy intended to improve lesion clearance
The goal is to support more effective management of early skin lesions and strengthen evidence for topical treatment options in routine dermatologic care.
Inflammatory Fungal Skin Infection Research
Another trial at ZENTderma examines treatment options for moderately to severely inflamed candidiasis of the skin. This research compares therapies used to relieve symptoms and control the underlying fungal infection, while also evaluating tolerability.
- Candidiasis of the skin
- Inflammatory fungal infection management
- Assessing treatment effectiveness and safety
By studying this condition, the site contributes to better understanding of how topical medicines can help patients with irritated, infected skin.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Aresus Pharma GmbH1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ZENTderma
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Adaptive Phase 3 Study to Evaluate the Efficacy and Safety of Sinecatechins (Defined Extract of Green Tea Leaves) Ointment in Adult Patients with Actinic Keratosis of the Scalp and the Face. | Aresus Pharma GmbH | Phase III | Recruiting | Sep 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Betamethasone Dipropionate | 1 | Unknown | 2022-03-08 | 2022-03-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.